# Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)

> **NCT02078973** · PHASE2 · COMPLETED · sponsor: **Regional Hospital Holstebro** · enrollment: 15 (actual)

## Conditions studied

- Nephropathy

## Interventions

- **DRUG:** 15 mg tolvaptan
- **DRUG:** 30 mg tolvaptan
- **DRUG:** 45 mg tolvaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02078973
- **Lead sponsor:** Regional Hospital Holstebro
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078973, "Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02078973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*